Armistice Capital, LLC has filed its 13F form on May 15, 2025 for Q1 2025 where it was disclosed a total value porftolio of $6.56 Billion distributed in 230 stocks.
Among their holdings, we can observe that their the top five positions include companies like: Ptc Therapeutics, Inc. with a value of $277M, Supernus Pharmaceuticals, Inc. with a value of $170M, Travere Therapeutics, Inc. with a value of $159M, Immunovant, Inc. with a value of $124M, and Neurocrine Biosciences Inc with a value of $111M.
Examining the 13F form we can see an decrease of $518M in the current position value, from $7.08B to 6.56B .
Armistice Capital, LLC is based out at New York, NY
Below you can find more details about Armistice Capital, LLC portfolio as well as his latest detailed transactions.
Portfolio value
$6.56 Billion
$2.71 Billion
$2.54 Billion
$435 Million
$368 Million
$365 Million
$53.2 Million
$45.8 Million
$34.8 Million
$16.3 Million
Stock Market Cap.
Holding Value (Reported)
# of Shares.
Last Trade
Trade History
-
$0
0.0% of portfolio
-
Q1 2025
New
-
$0
0.0% of portfolio
-
Q1 2025
Added 1.42%
-
$0
0.0% of portfolio
-
Q1 2025
Added 1,411.03%
-
$0
0.0% of portfolio
-
Q3 2024
Reduced 87.5%
Creative Med Technology Hldg
-
$0
0.0% of portfolio
-
Q1 2025
New
-
$0
0.0% of portfolio
-
Q1 2025
Added 156.1%
-
$0
0.0% of portfolio
-
Q1 2025
Reduced 61.6%
-
$0
0.0% of portfolio
-
Q1 2025
Reduced 85.81%
$0
$128,000
0.0% of portfolio
715,000
Q2 2023
Reduced -0.0%
-
$0
0.0% of portfolio
-
Q1 2025
New
-
$0
0.0% of portfolio
-
Q1 2025
New
-
$0
0.0% of portfolio
-
Q1 2025
New
-
$0
0.0% of portfolio
-
Q1 2025
Added 146.15%
-
$0
0.0% of portfolio
-
Q1 2025
New
-
$0
0.0% of portfolio
-
Q1 2025
Added 2.4%
-
$0
0.0% of portfolio
-
Q2 2023
Reduced -0.0%
-
$0
0.0% of portfolio
-
Q1 2025
Added 0.07%
Corbus Pharmaceuticals Hldgs
-
$0
0.0% of portfolio
-
Q1 2025
Added 5.93%
-
$0
0.0% of portfolio
-
Q1 2025
New
Cero Therapeutics Hldgs Inc
-
$0
0.0% of portfolio
-
Q1 2025
New
$0
$0
0.0% of portfolio
58,333
Q2 2024
Reduced 91.67%
-
$0
0.0% of portfolio
-
Q1 2025
Added 94.3%
Calidi Biotherapeutics Inc
-
$0
0.0% of portfolio
-
Q1 2025
New
$0
$2,000
0.0% of portfolio
25,000
Q1 2025
Reduced 93.33%
Brainstorm Cell Therapeutics
-
$0
0.0% of portfolio
-
Q1 2025
New
Accelerate Diagnostics Inc
-
$0
0.0% of portfolio
-
Q1 2025
Reduced 9.57%
-
$0
0.0% of portfolio
-
Q1 2025
Added 5.95%
-
$0
0.0% of portfolio
-
Q1 2025
Added 1.28%
-
$0
0.0% of portfolio
-
Q1 2025
New
-
$0
0.0% of portfolio
-
Q2 2023
Reduced -0.0%
$0
$277,000
0.0% of portfolio
1,261,058
Q2 2023
Reduced -0.0%
-
$0
0.0% of portfolio
-
Q1 2025
Reduced 11.44%
-
$0
0.0% of portfolio
-
Q1 2025
New
-
$0
0.0% of portfolio
-
Q1 2025
Reduced 16.12%
-
$0
0.0% of portfolio
-
Q1 2025
Added 37.39%
$0
$1,000
0.0% of portfolio
50,000
Q1 2024
Reduced 95.0%
-
$0
0.0% of portfolio
-
Q1 2025
New
-
$0
0.0% of portfolio
-
Q1 2025
Reduced 27.86%
$0
$0
0.0% of portfolio
12,500
Q3 2024
Reduced 97.5%
Mural Oncology Pub LTD CO
-
$0
0.0% of portfolio
-
Q1 2025
Added 1.29%
-
$0
0.0% of portfolio
-
Q1 2025
Added 21.62%
-
$0
0.0% of portfolio
-
Q1 2025
Added 293.59%
-
$0
0.0% of portfolio
-
Q2 2023
Reduced -0.0%
$0
$247,000
0.0% of portfolio
550,000
Q2 2023
Reduced -0.0%
$142M
$49,000
0.0% of portfolio
104,000
Q4 2024
Added 4.0%
-
$0
0.0% of portfolio
-
Q2 2023
Reduced -0.0%
-
$0
0.0% of portfolio
-
Q1 2025
New
-
$0
0.0% of portfolio
-
Q1 2025
Reduced 15.76%
Kestra Med Technologies LTD
-
$0
0.0% of portfolio
-
Q1 2025
New
-
$0
0.0% of portfolio
-
Q1 2025
Reduced 10.22%
